5 November 2023
RNZ's Kim Hill discusses the results of the Malaghan Institute's phase 1 clinical trial.
Michele Leggott / Dr Robert Weinkove / Prof Carl June
Results have been released for Malaghan Institute's ground-breaking CAR T-cell cancer therapy trial, and they are promising.
The therapy reprogrammes a patient's own immune cells to recognise and kill cancer.
Discussing the treatment and trial are Professor Carl June from the University of Pennsylvania who pioneered the therapy and Dr Robert Weinkove, who leads Malaghan's CAR T-cell programme.
They are joined by writer and poet Michele Leggott, who is twelve months into the trial, for an update on her progress.
Related articles
Malaghan CAR T programme wins KiwiNet Research Commercialisation Award
23 October 2025
Read more
New funding supports cutting-edge research into immune cell metabolism
13 October 2025
Read more
Study explores wearable devices to improve blood cancer patient monitoring
8 October 2025
Read more
The Detail: The viral drift of misinformation
29 September 2025
Read more
Blood, sweat and cells: The making of New Zealand’s first CAR T-cell trial
24 September 2025
Read more
Funding boost to improve lung cancer treatment outcomes in Aotearoa New Zealand
5 September 2025
Read more